AstraZeneca submitted data for MHRA approval, says UK Health Minister

UK health secretary said that AstraZeneca had submitted a full data package about its Covid-19 vaccine to the Medicines and Healthcare products Regulatory Agency (MHRA) for approval

AstraZeneca
Photo: Reuters
ANI Europe
1 min read Last Updated : Dec 24 2020 | 7:43 AM IST

Don't want to miss the best from Business Standard?

The United Kingdom's (UK) health secretary, Matt Hancock, on Wednesday said that AstraZeneca had submitted a full data package about its Covid-19 vaccine to the Medicines and Healthcare products Regulatory Agency (MHRA) for approval.

"I'm delighted that the University of Oxford/ AstraZeneca vaccine, developed in the UK, has submitted its full data package to the MHRA for approval. This is the next step towards a decision on the deployment of the coronavirus vaccine," Matt Hancock, UK Health Minister wrote in a tweet.

"Amid all of this difficulty, the great hope for 2021 is of course on the vaccine," he said.

He further stated, "This is the next step towards a decision on the deployment of the vaccine, which is already being manufactured including here in the UK."

We are of course continuing to deploy the Pfizer/BioNTech vaccine, which is being delivered now from over 500 sites all across the UK, and we're adding more all of the time and accelerating the roll-out," Hancock added.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :AstraZenecaCoronavirus VaccineBritain

First Published: Dec 24 2020 | 7:29 AM IST

Next Story